MaxCyte Signs Strategic Platform License Agreement With Moonlight Bio To Advance T Cell Therapy Development

MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced the signing of a Strategic Platform License (SPL) agreement with Moonlight Bio, a preclinical-stage biotechnology company based in Seattle, Washington.

Moonlight Bio will deploy MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support the scalable development and manufacturing of its T cell therapy pipeline.